Bravo drill results at Luanga platinum-palladium site highlight project growth

Bravo Mining reported drill results from its Luanga platinum-palladium project in Brazil, including DDH26LU312: 51m at 3.67 g/t PGM+gold, 0.14 g/t rhodium and 0.33% nickel from 259m. The company said infill/extensional drilling targets upgrading inferred to indicated resources and plans a prefeasibility study in Q3. Shares rose 4% to $3.40.

Original reporting
Published Jul 6, 2026, 7:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 7:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bravo drill results at Luanga platinum-palladium site highlight project growth — source image
Decision brief

The 30-second read

$BRVOBullishMed
01

Why it matters

The disclosed intercepts (notably DDH26LU312 and other Central-sector holes) are intended to demonstrate continuity and thickness at depth, supporting the inferred-to-indicated upgrade pathway and increasing the probability of a constructive Q3 PFS.

02

Market read

Traders can use the new drill intercepts and stated upgrade/PFS timeline as a near-term catalyst for BRVO positioning, with follow-through dependent on subsequent assay density and PFS outcomes.

03

What to watch

Key next swing factors are metallurgical testwork, open-pit design constraints, and whether infill drilling truly supports conversion to indicated resources at the required cutoffs for a bankable PFS.

Relevance 7/10Novelty 6/10Timing: ahead of Q3 prefeasibility study publication

Background

Bravo is advancing its Luanga platinum-palladium project in Brazil’s Carajás mineral province and is running infill/extension drilling to upgrade resources ahead of a prefeasibility study.

Company-level read

Ticker impact

$BRVOBullishMedium confidence
Context

Bravo reported Luanga infill/extension drill results, including DDH26LU312 grading 3.67 g/t PGM+gold over 51 m, supporting a resource upgrade toward a Q3 PFS.

Expected impact

Near-term upside bias for BRVO as investors price higher odds of resource upgrade and a constructive PFS; volatility likely around subsequent assay and PFS milestones.

Evidence & confidence

The article provides specific drill intercepts and states the program’s purpose (inferred→indicated) plus a stated timing target (publish PFS in Q3), which are direct catalysts for valuation and sentiment.

Market effects

Positive read-through for PGM/rhodium/nickel project development sentiment in Brazil’s Carajás province, though impact is company-specific.

Highlights ongoing exploration momentum in Pará state’s Carajás mineral province, potentially supporting local investor interest.

Reinforces supply-side optionality for palladium/platinum/rhodium/nickel outside top producers, but scale is still contingent on PFS and resource upgrade.

Counterpoint

Drill results alone may not de-risk economics; investors may discount if metallurgical recovery, continuity at pit limits, or capex/opex assumptions fail in the PEA/PFS.

Key entities

  • Bravo Mining

    TSXV/OTC-listed developer advancing Luanga; released the drill results and reiterated the Q3 prefeasibility study timeline.

  • Luanga project

    Brazil PGM (palladium/platinum/rhodium) and nickel deposit in the Carajás mineral province; target of infill/extension drilling and upcoming PFS.

Related articles

$BRVOMed

palladium site highlight project growth

Bravo Mining reported drill results from its Luanga PGM project in Brazil, highlighting DDH26LU312 with 51m at 3.67 g/t PGM+gold, 0.14 g/t rhodium and 0.33% nickel from 259m. The company plans a prefeasibility study in Q3 and aims to upgrade resources. Bravo shares rose 4% to C$3.40; Luanga PEA NPV(8%) $1.25B, IRR 50%.

$DJTMed

Nearly a dozen firms are paying up to $100,000 per month for early access Truth Social posts

Trump Media & Technology Group said more than 10 customers have signed up for Truth API, giving Wall Street traders early access to Truth Social posts from top users, including Trump, for $60,000 to $100,000 per month. Interim CEO Kevin McGurn said most customers are high-frequency firms and expansion talks are underway. The company reported a $238 million loss in April-June.

$BCAXMed

Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances

Bicara Therapeutics (NASDAQ:BCAX) shares rose about 3.3% pre-market after the company said enrollment is progressing in its pivotal FORTIFI-HN01 study and it remains on track for an interim analysis in mid-2027. Bicara reported Q2 2026 net loss of $55.4M, or $0.82 per share, with higher R&D and G&A. Cash and securities were $497.3M, expected to fund operations into 1H 2029.

$ABUSMed

Arbutus Advances Imdusiran; FDA Aligns On Phase 2b Trial Design

Arbutus Biopharma (ABUS) reported Q2 2026 results and said the FDA aligned with its proposed Phase 2b trial design for imdusiran in chronic hepatitis B, following Fast Track designation. The company received about $178.4 million from its Moderna settlement share and plans potential share repurchases up to about $230 million. Q2 revenue was $1.0 million; net loss $5.1 million.